{ "title": "Peptide legal status by country", "publisher": "Peptlas Research Team", "url": "https://peptlas.com/peptide-status-by-country/", "license": { "name": "CC BY 4.0", "url": "https://creativecommons.org/licenses/by/4.0/" }, "attribution": "Peptlas (https://peptlas.com/peptide-status-by-country/)", "last_verified": "2026-10-15", "jurisdictions": [ { "authority": "United States (FDA)", "regulator": "FDA" }, { "authority": "Australia (TGA)", "regulator": "TGA" }, { "authority": "United Kingdom (MHRA)", "regulator": "MHRA" }, { "authority": "European Union (EMA)", "regulator": "EMA" }, { "authority": "Canada (Health Canada)", "regulator": "Health Canada" }, { "authority": "Sport / anti-doping (WADA)", "regulator": "WADA" } ], "statuses": { "compounding_legal": { "label": "Compounding-legal", "meaning": "A licensed pharmacy may compound it on prescription: it is on the FDA 503A bulk-substances list or is an ingredient of an FDA-approved drug that is not on the market. This is not the same as being an FDA-approved drug." }, "under_review": { "label": "Under review", "meaning": "Actively before the FDA advisory committee; a decision is pending and the status can move." }, "in_limbo": { "label": "In limbo", "meaning": "Moved on paper - nominated, removed from a restricted list, or recommended by an FDA committee - but not added to the 503A list. The headline implies a change; the legal status has not moved." }, "restricted": { "label": "Restricted", "meaning": "Prescription-only, banned, controlled, or under active FDA enforcement." }, "unscheduled": { "label": "Unscheduled", "meaning": "No specific federal action; unaddressed at this time." } }, "rows": [ { "compound": "AOD-9604", "slug": "aod-9604", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from 503A Category 2 on Sep 27, 2024 after the nominations were withdrawn; PCAC voted 0-12 against the 503A list on Dec 4, 2024; in no category, not compoundable.", "entry_url": "https://peptlas.com/entries/aod-9604/", "last_verified": "2026-10-15" }, { "compound": "AOD-9604", "slug": "aod-9604", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Named in Schedule 4 (prescription only) of the Poisons Standard and in Appendix D item 5 (possession without authority is illegal), entries made by a 2015 scheduling decision.", "entry_url": "https://peptlas.com/entries/aod-9604/", "last_verified": "2026-10-15" }, { "compound": "AOD-9604", "slug": "aod-9604", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation (not in the MHRA products substance index); supply as a medicine would be unlicensed.", "entry_url": "https://peptlas.com/entries/aod-9604/", "last_verified": "2026-10-15" }, { "compound": "AOD-9604", "slug": "aod-9604", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation or orphan designation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement at member-state level.", "entry_url": "https://peptlas.com/entries/aod-9604/", "last_verified": "2026-10-15" }, { "compound": "AOD-9604", "slug": "aod-9604", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not in the Drug Product Database; Health Canada advisories in Aug and Dec 2025 list seized AOD-9604 among unauthorized injectable peptide drugs, which it regulates as prescription drugs.", "entry_url": "https://peptlas.com/entries/aod-9604/", "last_verified": "2026-10-15" }, { "compound": "AOD-9604", "slug": "aod-9604", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Named in S2.2.3 of the 2027 Prohibited List as a growth hormone fragment (\"e.g. AOD-9604 and hGH 176-191\"); prohibited at all times.", "entry_url": "https://peptlas.com/entries/aod-9604/", "last_verified": "2026-10-15" }, { "compound": "BPC-157", "slug": "bpc-157", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.", "entry_url": "https://peptlas.com/entries/bpc-157/", "last_verified": "2026-09-22" }, { "compound": "BPC-157", "slug": "bpc-157", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Reported as Schedule 4 (prescription-only) under the Poisons Standard.", "entry_url": "https://peptlas.com/entries/bpc-157/", "last_verified": "2026-09-22" }, { "compound": "BPC-157", "slug": "bpc-157", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/bpc-157/", "last_verified": "2026-09-22" }, { "compound": "BPC-157", "slug": "bpc-157", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/bpc-157/", "last_verified": "2026-09-22" }, { "compound": "BPC-157", "slug": "bpc-157", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not an authorized drug; Health Canada's April 2026 advisory names BPC-157 among unauthorized injectable peptides and states such products are illegal to sell in Canada.", "entry_url": "https://peptlas.com/entries/bpc-157/", "last_verified": "2026-09-22" }, { "compound": "BPC-157", "slug": "bpc-157", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times under category S0 (non-approved substances). Unchanged on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027).", "entry_url": "https://peptlas.com/entries/bpc-157/", "last_verified": "2026-09-22" }, { "compound": "Cagrilintide", "slug": "cagrilintide", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "Investigational; not approved, not compoundable (not a component of an approved drug, not an eligible bulk substance). The CagriSema NDA is under FDA review; warning letters to sellers, including products sold under coded names.", "entry_url": "https://peptlas.com/entries/cagrilintide/", "last_verified": "2026-10-09" }, { "compound": "Cagrilintide", "slug": "cagrilintide", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named or scheduled in the Poisons Standard.", "entry_url": "https://peptlas.com/entries/cagrilintide/", "last_verified": "2026-10-09" }, { "compound": "Cagrilintide", "slug": "cagrilintide", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/cagrilintide/", "last_verified": "2026-10-09" }, { "compound": "Cagrilintide", "slug": "cagrilintide", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; not on EMA's August 2026 list of applications under CHMP evaluation; sale as a medicine unlawful EU-wide, with enforcement at member-state level.", "entry_url": "https://peptlas.com/entries/cagrilintide/", "last_verified": "2026-10-09" }, { "compound": "Cagrilintide", "slug": "cagrilintide", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "under_review", "status_label": "Under review", "note": "Cagrilintide/semaglutide new drug submission (Novo Nordisk) accepted into Health Canada review in March 2026; no cagrilintide product yet authorized in the Drug Product Database.", "entry_url": "https://peptlas.com/entries/cagrilintide/", "last_verified": "2026-10-09" }, { "compound": "Cagrilintide", "slug": "cagrilintide", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times, but not listed by name - captured by the S0 catch-all for substances with no regulatory approval for human use.", "entry_url": "https://peptlas.com/entries/cagrilintide/", "last_verified": "2026-10-09" }, { "compound": "CJC-1295", "slug": "cjc-1295", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from Category 2 (~Sept 2024); PCAC voted against inclusion Dec 4, 2024; not on the 503A list; no USP monograph.", "entry_url": "https://peptlas.com/entries/cjc-1295/", "last_verified": "2026-09-22" }, { "compound": "CJC-1295", "slug": "cjc-1295", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Reported as Schedule 4 (prescription-only) under the Poisons Standard.", "entry_url": "https://peptlas.com/entries/cjc-1295/", "last_verified": "2026-09-22" }, { "compound": "CJC-1295", "slug": "cjc-1295", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/cjc-1295/", "last_verified": "2026-09-22" }, { "compound": "CJC-1295", "slug": "cjc-1295", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/cjc-1295/", "last_verified": "2026-09-22" }, { "compound": "CJC-1295", "slug": "cjc-1295", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized by Health Canada; named in an April 2026 public advisory on unauthorized injectable peptides, which states such products are illegal to sell and reports seizures.", "entry_url": "https://peptlas.com/entries/cjc-1295/", "last_verified": "2026-09-22" }, { "compound": "CJC-1295", "slug": "cjc-1295", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times under S2 as a growth-hormone-releasing factor analogue.", "entry_url": "https://peptlas.com/entries/cjc-1295/", "last_verified": "2026-09-22" }, { "compound": "Dihexa", "slug": "dihexa", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from 503A Category 2 on Apr 22, 2026 after the nomination was withdrawn; not on the 503A list; PCAC review expected before end of Feb 2027.", "entry_url": "https://peptlas.com/entries/dihexa/", "last_verified": "2026-10-15" }, { "compound": "Dihexa", "slug": "dihexa", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard (October 2026) and no product on the ARTG; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/dihexa/", "last_verified": "2026-10-15" }, { "compound": "Dihexa", "slug": "dihexa", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation (not in the MHRA products substance index); supply as a medicine would be unlicensed.", "entry_url": "https://peptlas.com/entries/dihexa/", "last_verified": "2026-10-15" }, { "compound": "Dihexa", "slug": "dihexa", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation or orphan designation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement at member-state level.", "entry_url": "https://peptlas.com/entries/dihexa/", "last_verified": "2026-10-15" }, { "compound": "Dihexa", "slug": "dihexa", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "No product in the Drug Product Database, so it has no DIN and cannot lawfully be sold as a drug; no Health Canada advisory names it.", "entry_url": "https://peptlas.com/entries/dihexa/", "last_verified": "2026-10-15" }, { "compound": "Dihexa", "slug": "dihexa", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances (2027 List).", "entry_url": "https://peptlas.com/entries/dihexa/", "last_verified": "2026-10-15" }, { "compound": "Emideltide (DSIP)", "slug": "emideltide", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC voted against adding it on Jul 24, 2026 (6-7, 1 abstention). No further FDA action is scheduled.", "entry_url": "https://peptlas.com/entries/emideltide/", "last_verified": "2026-09-22" }, { "compound": "Emideltide (DSIP)", "slug": "emideltide", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/emideltide/", "last_verified": "2026-09-22" }, { "compound": "Emideltide (DSIP)", "slug": "emideltide", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/emideltide/", "last_verified": "2026-09-22" }, { "compound": "Emideltide (DSIP)", "slug": "emideltide", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation for emideltide (DSIP); sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/emideltide/", "last_verified": "2026-09-22" }, { "compound": "Emideltide (DSIP)", "slug": "emideltide", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized in Canada; Health Canada's April 2026 advisory names DSIP among unauthorized injectable peptide drugs that are illegal to sell.", "entry_url": "https://peptlas.com/entries/emideltide/", "last_verified": "2026-09-22" }, { "compound": "Emideltide (DSIP)", "slug": "emideltide", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances.", "entry_url": "https://peptlas.com/entries/emideltide/", "last_verified": "2026-09-22" }, { "compound": "Epitalon", "slug": "epitalon", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (7-4, 1 abstention); the recommendation is advisory and the FDA has not acted.", "entry_url": "https://peptlas.com/entries/epitalon/", "last_verified": "2026-09-22" }, { "compound": "Epitalon", "slug": "epitalon", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/epitalon/", "last_verified": "2026-09-22" }, { "compound": "Epitalon", "slug": "epitalon", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/epitalon/", "last_verified": "2026-09-22" }, { "compound": "Epitalon", "slug": "epitalon", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/epitalon/", "last_verified": "2026-09-22" }, { "compound": "Epitalon", "slug": "epitalon", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Named in Health Canada's April 2026 advisory on unauthorized injectable peptides; absent from the Drug Product Database, so sale for human use is illegal under the Food and Drugs Act.", "entry_url": "https://peptlas.com/entries/epitalon/", "last_verified": "2026-09-22" }, { "compound": "Epitalon", "slug": "epitalon", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances.", "entry_url": "https://peptlas.com/entries/epitalon/", "last_verified": "2026-09-22" }, { "compound": "GHK-Cu", "slug": "ghk-cu", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Topical route ≈ Category 1; injectable route removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027.", "entry_url": "https://peptlas.com/entries/ghk-cu/", "last_verified": "2026-09-22" }, { "compound": "GHK-Cu", "slug": "ghk-cu", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard; topical cosmetic products are freely available.", "entry_url": "https://peptlas.com/entries/ghk-cu/", "last_verified": "2026-09-22" }, { "compound": "GHK-Cu", "slug": "ghk-cu", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply as a medicine is unlicensed, though copper tripeptide-1 remains a permitted cosmetic ingredient under GB cosmetics law.", "entry_url": "https://peptlas.com/entries/ghk-cu/", "last_verified": "2026-09-22" }, { "compound": "GHK-Cu", "slug": "ghk-cu", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/ghk-cu/", "last_verified": "2026-09-22" }, { "compound": "GHK-Cu", "slug": "ghk-cu", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not in the Drug Product Database; Health Canada recalled GHK-Cu powder as an unauthorized active pharmaceutical ingredient in May 2026.", "entry_url": "https://peptlas.com/entries/ghk-cu/", "last_verified": "2026-09-22" }, { "compound": "GHK-Cu", "slug": "ghk-cu", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not explicitly named on the Prohibited List.", "entry_url": "https://peptlas.com/entries/ghk-cu/", "last_verified": "2026-09-22" }, { "compound": "Ipamorelin", "slug": "ipamorelin", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from Category 2 (~Sept 2024); PCAC voted against 503A inclusion Oct 29, 2024; not on any bulks list; no separate ban.", "entry_url": "https://peptlas.com/entries/ipamorelin/", "last_verified": "2026-09-22" }, { "compound": "Ipamorelin", "slug": "ipamorelin", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Reported as Schedule 4 (prescription-only) under the Poisons Standard.", "entry_url": "https://peptlas.com/entries/ipamorelin/", "last_verified": "2026-09-22" }, { "compound": "Ipamorelin", "slug": "ipamorelin", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/ipamorelin/", "last_verified": "2026-09-22" }, { "compound": "Ipamorelin", "slug": "ipamorelin", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement at member-state level.", "entry_url": "https://peptlas.com/entries/ipamorelin/", "last_verified": "2026-09-22" }, { "compound": "Ipamorelin", "slug": "ipamorelin", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized for sale; Health Canada's April 2026 advisory names ipamorelin as an unauthorized injectable peptide drug that is illegal to sell in Canada.", "entry_url": "https://peptlas.com/entries/ipamorelin/", "last_verified": "2026-09-22" }, { "compound": "Ipamorelin", "slug": "ipamorelin", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times under S2 as a growth-hormone secretagogue.", "entry_url": "https://peptlas.com/entries/ipamorelin/", "last_verified": "2026-09-22" }, { "compound": "Kisspeptin-10", "slug": "kisspeptin", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "503A Category 2 since Sep 29, 2023 - FDA would consider taking action against a pharmacy that compounds with it. PCAC voted 0-11 against adding it to the 503A bulks list (Oct 29, 2024); no final rule yet. No FDA-approved kisspeptin product.", "entry_url": "https://peptlas.com/entries/kisspeptin/", "last_verified": "2026-10-15" }, { "compound": "Kisspeptin-10", "slug": "kisspeptin", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard (October 2026) and no product on the ARTG; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/kisspeptin/", "last_verified": "2026-10-15" }, { "compound": "Kisspeptin-10", "slug": "kisspeptin", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; the MHRA products database holds no kisspeptin product (its only matches are other medicines' documents that mention kisspeptin).", "entry_url": "https://peptlas.com/entries/kisspeptin/", "last_verified": "2026-10-15" }, { "compound": "Kisspeptin-10", "slug": "kisspeptin", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation and no EU orphan designation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement at member-state level.", "entry_url": "https://peptlas.com/entries/kisspeptin/", "last_verified": "2026-10-15" }, { "compound": "Kisspeptin-10", "slug": "kisspeptin", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not in the Drug Product Database; Health Canada has listed kisspeptin products among unauthorized products seized in Calgary (Apr 2025), from Canada Peptide (Aug 2025) and at Rize Fitness (Dec 2025).", "entry_url": "https://peptlas.com/entries/kisspeptin/", "last_verified": "2026-10-15" }, { "compound": "Kisspeptin-10", "slug": "kisspeptin", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Named in S2.2.1: \"kisspeptin and its agonist analogues\" are testosterone-stimulating peptides prohibited at all times in males (2026 and 2027 Lists).", "entry_url": "https://peptlas.com/entries/kisspeptin/", "last_verified": "2026-10-15" }, { "compound": "KPV", "slug": "kpv", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.", "entry_url": "https://peptlas.com/entries/kpv/", "last_verified": "2026-09-22" }, { "compound": "KPV", "slug": "kpv", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/kpv/", "last_verified": "2026-09-22" }, { "compound": "KPV", "slug": "kpv", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/kpv/", "last_verified": "2026-09-22" }, { "compound": "KPV", "slug": "kpv", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; not found in EMA's centralised medicines database, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/kpv/", "last_verified": "2026-09-22" }, { "compound": "KPV", "slug": "kpv", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized for sale; listed in an April 2026 Health Canada advisory among unauthorized injectable peptide drugs it has seized, with peptides generally regulated as prescription drugs in Canada.", "entry_url": "https://peptlas.com/entries/kpv/", "last_verified": "2026-09-22" }, { "compound": "KPV", "slug": "kpv", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances.", "entry_url": "https://peptlas.com/entries/kpv/", "last_verified": "2026-09-22" }, { "compound": "LL-37 (cathelicidin)", "slug": "ll-37", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from 503A Category 2 on Apr 22, 2026 after the nomination was withdrawn; not on the 503A list; PCAC review expected before end of Feb 2027.", "entry_url": "https://peptlas.com/entries/ll-37/", "last_verified": "2026-10-15" }, { "compound": "LL-37 (cathelicidin)", "slug": "ll-37", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard (October 2026) and no product on the ARTG; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/ll-37/", "last_verified": "2026-10-15" }, { "compound": "LL-37 (cathelicidin)", "slug": "ll-37", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation (not in the MHRA products substance index); supply as a medicine would be unlicensed.", "entry_url": "https://peptlas.com/entries/ll-37/", "last_verified": "2026-10-15" }, { "compound": "LL-37 (cathelicidin)", "slug": "ll-37", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation or orphan designation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement at member-state level.", "entry_url": "https://peptlas.com/entries/ll-37/", "last_verified": "2026-10-15" }, { "compound": "LL-37 (cathelicidin)", "slug": "ll-37", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not in the Drug Product Database; a Health Canada advisory (Aug 1, 2025) lists seized LL-37 among unauthorized injectable peptide drugs, which it regulates as prescription drugs.", "entry_url": "https://peptlas.com/entries/ll-37/", "last_verified": "2026-10-15" }, { "compound": "LL-37 (cathelicidin)", "slug": "ll-37", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances (2027 List).", "entry_url": "https://peptlas.com/entries/ll-37/", "last_verified": "2026-10-15" }, { "compound": "Melanotan II", "slug": "melanotan-2", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on Category 1 / the 503A list; being moved out of Category 2; PCAC review expected before end of Feb 2027. Not DEA-scheduled.", "entry_url": "https://peptlas.com/entries/melanotan-2/", "last_verified": "2026-09-22" }, { "compound": "Melanotan II", "slug": "melanotan-2", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Schedule 4 (prescription-only); no products registered on the ARTG; TGA has issued infringement notices for unlawful supply.", "entry_url": "https://peptlas.com/entries/melanotan-2/", "last_verified": "2026-09-22" }, { "compound": "Melanotan II", "slug": "melanotan-2", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; MHRA has repeatedly removed melanotan products from sale for over 10 years, though nasal sprays without medicinal claims are not generally regulated as medicines.", "entry_url": "https://peptlas.com/entries/melanotan-2/", "last_verified": "2026-09-22" }, { "compound": "Melanotan II", "slug": "melanotan-2", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation - no melanotan II entry in EMA's centrally authorised medicines database; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/melanotan-2/", "last_verified": "2026-09-22" }, { "compound": "Melanotan II", "slug": "melanotan-2", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized for sale; Health Canada names Melanotan I and II among unauthorized injectable peptide drugs it has seized, warning that unauthorized drug products are illegal in Canada.", "entry_url": "https://peptlas.com/entries/melanotan-2/", "last_verified": "2026-09-22" }, { "compound": "Melanotan II", "slug": "melanotan-2", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times, but not listed by name - captured by the S0 catch-all for non-approved substances (also argued under S2).", "entry_url": "https://peptlas.com/entries/melanotan-2/", "last_verified": "2026-09-22" }, { "compound": "MOTS-c", "slug": "mots-c", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (7-5, 2 abstentions); the recommendation is advisory and the FDA has not acted.", "entry_url": "https://peptlas.com/entries/mots-c/", "last_verified": "2026-09-22" }, { "compound": "MOTS-c", "slug": "mots-c", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/mots-c/", "last_verified": "2026-09-22" }, { "compound": "MOTS-c", "slug": "mots-c", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/mots-c/", "last_verified": "2026-09-22" }, { "compound": "MOTS-c", "slug": "mots-c", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation in the Union Register; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/mots-c/", "last_verified": "2026-09-22" }, { "compound": "MOTS-c", "slug": "mots-c", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Named in Health Canada's April 2026 advisory on unauthorized injectable peptides; unauthorized drug products are illegal to sell in Canada.", "entry_url": "https://peptlas.com/entries/mots-c/", "last_verified": "2026-09-22" }, { "compound": "MOTS-c", "slug": "mots-c", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Explicitly named on the 2026 Prohibited List under S4.4.1 (metabolic modulators / AMPK activators); prohibited at all times. Still listed on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027).", "entry_url": "https://peptlas.com/entries/mots-c/", "last_verified": "2026-09-22" }, { "compound": "NAD+", "slug": "nad-plus", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Proposed for non-inclusion (2019); no final rule and no ban; oral sold as a supplement; injectable compounded in a gray area.", "entry_url": "https://peptlas.com/entries/nad-plus/", "last_verified": "2026-09-22" }, { "compound": "NAD+", "slug": "nad-plus", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Per an April 2025 TGA safety alert, NAD/NAD+/NADH are not permitted ingredients in listed medicines.", "entry_url": "https://peptlas.com/entries/nad-plus/", "last_verified": "2026-09-22" }, { "compound": "NAD+", "slug": "nad-plus", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; injectable NAD+ is supplied only as an unlicensed 'special' on a prescriber's order, while oral NAD+ is sold under food-supplement rules.", "entry_url": "https://peptlas.com/entries/nad-plus/", "last_verified": "2026-09-22" }, { "compound": "NAD+", "slug": "nad-plus", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; injectable NAD+ cannot be marketed as a medicine EU-wide, with enforcement handled at member-state level; oral NAD+ circulates under food-supplement law.", "entry_url": "https://peptlas.com/entries/nad-plus/", "last_verified": "2026-09-22" }, { "compound": "NAD+", "slug": "nad-plus", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "No approved injectable NAD+ in the Drug Product Database; an April 2026 Health Canada advisory lists NAD+ among unauthorized injectable drugs illegal to sell; oral NAD+ is regulated as a natural health product.", "entry_url": "https://peptlas.com/entries/nad-plus/", "last_verified": "2026-09-22" }, { "compound": "NAD+", "slug": "nad-plus", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not named on the Prohibited List, but IV infusions over 100 mL per 12 hours are prohibited as a method (M2.2).", "entry_url": "https://peptlas.com/entries/nad-plus/", "last_verified": "2026-09-22" }, { "compound": "PT-141 (bremelanotide)", "slug": "pt-141", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "FDA-approved prescription drug: Vyleesi, NDA 210557, approved Jun 21, 2019. As a component of that drug it may be 503A-compounded for an individual patient, but not as regular copies of Vyleesi while it is marketed. Aug 24, 2026: FDA warning letters to five online \"research peptide\" sellers name PT-141.", "entry_url": "https://peptlas.com/entries/pt-141/", "last_verified": "2026-10-15" }, { "compound": "PT-141 (bremelanotide)", "slug": "pt-141", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard (October 2026) and no product on the ARTG; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/pt-141/", "last_verified": "2026-10-15" }, { "compound": "PT-141 (bremelanotide)", "slug": "pt-141", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation (no bremelanotide product in the MHRA Products database); supply as a medicine would be unlicensed.", "entry_url": "https://peptlas.com/entries/pt-141/", "last_verified": "2026-10-15" }, { "compound": "PT-141 (bremelanotide)", "slug": "pt-141", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation: absent from the Union Register, and EMA's medicines data lists no application for it. Enforcement against unlicensed supply is handled at member-state level.", "entry_url": "https://peptlas.com/entries/pt-141/", "last_verified": "2026-10-15" }, { "compound": "PT-141 (bremelanotide)", "slug": "pt-141", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "No authorized product in the Drug Product Database; Health Canada named bremelanotide among unauthorized injectable peptide drugs seized from Canada Peptide (advisory updated Aug 1, 2025).", "entry_url": "https://peptlas.com/entries/pt-141/", "last_verified": "2026-10-15" }, { "compound": "PT-141 (bremelanotide)", "slug": "pt-141", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not named on the 2026 or 2027 Prohibited List or the 2027 Monitoring Program; S0 covers only substances with no government approval for human use, and bremelanotide is FDA-approved.", "entry_url": "https://peptlas.com/entries/pt-141/", "last_verified": "2026-10-15" }, { "compound": "Retatrutide", "slug": "retatrutide", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "Investigational; not approved, not compoundable (never on the shortage list, not an eligible bulk substance). FDA warning letters to sellers, including products sold under coded names.", "entry_url": "https://peptlas.com/entries/retatrutide/", "last_verified": "2026-10-09" }, { "compound": "Retatrutide", "slug": "retatrutide", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Not in the ARTG; the TGA names retatrutide among unapproved peptide products and takes enforcement action against unlawful import, compounding, supply and advertising. Victoria's Chief Health Officer issued a health alert on Jun 19, 2026 (still active) after six cases of acute liver injury since January 2026 in people who used products labelled Retatrutide, Reta, R-10 or R-20.", "entry_url": "https://peptlas.com/entries/retatrutide/", "last_verified": "2026-10-09" }, { "compound": "Retatrutide", "slug": "retatrutide", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine - MHRA has seized unlicensed retatrutide products in enforcement operations.", "entry_url": "https://peptlas.com/entries/retatrutide/", "last_verified": "2026-10-09" }, { "compound": "Retatrutide", "slug": "retatrutide", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation and no application under CHMP evaluation as of August 2026; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/retatrutide/", "last_verified": "2026-10-09" }, { "compound": "Retatrutide", "slug": "retatrutide", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized by Health Canada; named in an April 2026 advisory on unauthorized injectable peptide drugs - unauthorized drug products are illegal to sell in Canada.", "entry_url": "https://peptlas.com/entries/retatrutide/", "last_verified": "2026-10-09" }, { "compound": "Retatrutide", "slug": "retatrutide", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times, but not listed by name - captured by the S0 catch-all for substances with no regulatory approval for human use.", "entry_url": "https://peptlas.com/entries/retatrutide/", "last_verified": "2026-10-09" }, { "compound": "Selank", "slug": "selank", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from Category 2 (~Sept 2024); never in Category 1; not on the 503A list; no scheduled PCAC review.", "entry_url": "https://peptlas.com/entries/selank/", "last_verified": "2026-09-22" }, { "compound": "Selank", "slug": "selank", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named or scheduled in the Poisons Standard.", "entry_url": "https://peptlas.com/entries/selank/", "last_verified": "2026-09-22" }, { "compound": "Selank", "slug": "selank", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/selank/", "last_verified": "2026-09-22" }, { "compound": "Selank", "slug": "selank", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; Selank does not appear in the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/selank/", "last_verified": "2026-09-22" }, { "compound": "Selank", "slug": "selank", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized by Health Canada; a 2025 public advisory named Selank among seized unauthorized injectable peptide drugs, stating that selling unauthorized drugs is illegal in Canada.", "entry_url": "https://peptlas.com/entries/selank/", "last_verified": "2026-09-22" }, { "compound": "Selank", "slug": "selank", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Falls under S0 (non-approved substances); prohibited at all times for tested athletes.", "entry_url": "https://peptlas.com/entries/selank/", "last_verified": "2026-09-22" }, { "compound": "Semaglutide", "slug": "semaglutide", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "Enforcement discretion ended Apr 22, 2025 (503A, as announced; the FDA's Sep 2026 Empower letter dates it Apr 24) / May 22, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow patient-specific 503A exception remains. Sep 18, 2026: FDA warning letter to Empower Pharmacy over semaglutide/B12 injections that appear to be essentially copies.", "entry_url": "https://peptlas.com/entries/semaglutide/", "last_verified": "2026-10-09" }, { "compound": "Semaglutide", "slug": "semaglutide", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "GLP-1 analogues removed from the pharmacist compounding exemption effective Oct 1, 2024; remains Schedule 4.", "entry_url": "https://peptlas.com/entries/semaglutide/", "last_verified": "2026-10-09" }, { "compound": "Semaglutide", "slug": "semaglutide", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "Licensed prescription-only medicine; unlicensed copies may not be supplied where the licensed product can meet the patient's need, and MHRA enforces against unlicensed semaglutide products.", "entry_url": "https://peptlas.com/entries/semaglutide/", "last_verified": "2026-10-09" }, { "compound": "Semaglutide", "slug": "semaglutide", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "Centrally authorised prescription-only medicine; compounded versions hold no EU marketing authorisation, with enforcement against unlicensed supply handled at member-state level.", "entry_url": "https://peptlas.com/entries/semaglutide/", "last_verified": "2026-10-09" }, { "compound": "Semaglutide", "slug": "semaglutide", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Authorized prescription-only medicine (Ozempic, Wegovy), and generic semaglutide has been on sale since May 2026 (Dr. Reddy's from May 6, Apotex from May 14); both had Type II recalls in Aug-Sep 2026 (an impurity out of specification; a pen showing the wrong dose). Compounded copies of marketed drugs are not permitted outside a shortage, and Health Canada has recalled compounded semaglutide made with an unauthorized API.", "entry_url": "https://peptlas.com/entries/semaglutide/", "last_verified": "2026-10-09" }, { "compound": "Semaglutide", "slug": "semaglutide", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not prohibited; on the WADA Monitoring Program since 2024. WADA confirmed GLP-1 status is unchanged for 2027 (Sep 21, 2026).", "entry_url": "https://peptlas.com/entries/semaglutide/", "last_verified": "2026-10-09" }, { "compound": "Semax", "slug": "semax", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (8-5, 1 abstention); the recommendation is advisory and the FDA has not acted.", "entry_url": "https://peptlas.com/entries/semax/", "last_verified": "2026-09-22" }, { "compound": "Semax", "slug": "semax", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard; sits in a grey area.", "entry_url": "https://peptlas.com/entries/semax/", "last_verified": "2026-09-22" }, { "compound": "Semax", "slug": "semax", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/semax/", "last_verified": "2026-09-22" }, { "compound": "Semax", "slug": "semax", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/semax/", "last_verified": "2026-09-22" }, { "compound": "Semax", "slug": "semax", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "No Health Canada authorization; named in an August 2025 Health Canada seizure advisory on unauthorized injectable peptides, which cannot legally be sold in Canada.", "entry_url": "https://peptlas.com/entries/semax/", "last_verified": "2026-09-22" }, { "compound": "Semax", "slug": "semax", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances.", "entry_url": "https://peptlas.com/entries/semax/", "last_verified": "2026-09-22" }, { "compound": "Sermorelin", "slug": "sermorelin", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "compounding_legal", "status_label": "Compounding-legal", "note": "Not on the 503A bulks list or any interim category. Compounded as a component of Geref (NDAs 19-863, 20-443), whose approvals were withdrawn at the sponsor's request effective Jun 18, 2009; FDA found (Mar 4, 2013) it was not withdrawn for safety or effectiveness. FDA has not addressed whether a withdrawn approval still qualifies.", "entry_url": "https://peptlas.com/entries/sermorelin/", "last_verified": "2026-10-15" }, { "compound": "Sermorelin", "slug": "sermorelin", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Schedule 4 (prescription-only), named individually in the Poisons Standard (October 2026), and possession without authority is illegal (Appendix D). No product on the ARTG.", "entry_url": "https://peptlas.com/entries/sermorelin/", "last_verified": "2026-10-15" }, { "compound": "Sermorelin", "slug": "sermorelin", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/sermorelin/", "last_verified": "2026-10-15" }, { "compound": "Sermorelin", "slug": "sermorelin", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No centralised EU marketing authorisation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/sermorelin/", "last_verified": "2026-10-15" }, { "compound": "Sermorelin", "slug": "sermorelin", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Named on the Prescription Drug List ('Sermorelin or its salts', effective 2013-12-19); no product currently authorized in the Drug Product Database.", "entry_url": "https://peptlas.com/entries/sermorelin/", "last_verified": "2026-10-15" }, { "compound": "Sermorelin", "slug": "sermorelin", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Named in S2.2.4 (GHRH and its analogues) on the 2026 and 2027 Prohibited Lists; prohibited at all times.", "entry_url": "https://peptlas.com/entries/sermorelin/", "last_verified": "2026-10-15" }, { "compound": "SS-31 (elamipretide)", "slug": "ss-31", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "FDA-approved prescription drug: Forzinity (elamipretide hydrochloride) injection, NDA 215244, accelerated approval Sep 19, 2025. As a component of that drug, the HCl salt may be 503A-compounded for an individual patient, but not regularly or in inordinate amounts as essentially copies of Forzinity. FDA has called elamipretide (SS-31) acetate ineligible for 503A compounding (Dec 2025 warning letter). Not on any 503A category list.", "entry_url": "https://peptlas.com/entries/ss-31/", "last_verified": "2026-10-15" }, { "compound": "SS-31 (elamipretide)", "slug": "ss-31", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not individually named in the Poisons Standard (October 2026) and no product on the ARTG; supply for human use is unlawful without ARTG registration, and the TGA is enforcing against unapproved peptides.", "entry_url": "https://peptlas.com/entries/ss-31/", "last_verified": "2026-10-15" }, { "compound": "SS-31 (elamipretide)", "slug": "ss-31", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation (no result for elamipretide in the MHRA products database); supply as a medicine is unlicensed.", "entry_url": "https://peptlas.com/entries/ss-31/", "last_verified": "2026-10-15" }, { "compound": "SS-31 (elamipretide)", "slug": "ss-31", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation. Holds EU orphan designations for Barth syndrome (May 20, 2021) and myopathic mitochondrial DNA depletion syndrome (May 16, 2022), which EMA says do not mean the medicine is authorised.", "entry_url": "https://peptlas.com/entries/ss-31/", "last_verified": "2026-10-15" }, { "compound": "SS-31 (elamipretide)", "slug": "ss-31", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not in the Drug Product Database; Health Canada's Apr 9, 2026 advisory names SS-31 among unauthorized injectable peptide drugs it has seized.", "entry_url": "https://peptlas.com/entries/ss-31/", "last_verified": "2026-10-15" }, { "compound": "SS-31 (elamipretide)", "slug": "ss-31", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not named on the 2027 Prohibited List. S0 covers only substances with no current government approval for human therapeutic use, and elamipretide has been FDA-approved since Sep 2025.", "entry_url": "https://peptlas.com/entries/ss-31/", "last_verified": "2026-10-15" }, { "compound": "TB-500 (Thymosin Beta-4)", "slug": "tb-500", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.", "entry_url": "https://peptlas.com/entries/tb-500/", "last_verified": "2026-09-22" }, { "compound": "TB-500 (Thymosin Beta-4)", "slug": "tb-500", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Thymosin beta-4 treated as Schedule 4 (prescription-only) under the Poisons Standard.", "entry_url": "https://peptlas.com/entries/tb-500/", "last_verified": "2026-09-22" }, { "compound": "TB-500 (Thymosin Beta-4)", "slug": "tb-500", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/tb-500/", "last_verified": "2026-09-22" }, { "compound": "TB-500 (Thymosin Beta-4)", "slug": "tb-500", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/tb-500/", "last_verified": "2026-09-22" }, { "compound": "TB-500 (Thymosin Beta-4)", "slug": "tb-500", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized for sale; Health Canada has seized TB-500 among unauthorized injectable peptides and states selling unauthorized drugs is illegal in Canada.", "entry_url": "https://peptlas.com/entries/tb-500/", "last_verified": "2026-09-22" }, { "compound": "TB-500 (Thymosin Beta-4)", "slug": "tb-500", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Prohibited at all times as a growth factor / non-approved substance. Unchanged on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027).", "entry_url": "https://peptlas.com/entries/tb-500/", "last_verified": "2026-09-22" }, { "compound": "Tesamorelin", "slug": "tesamorelin", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "Approved Nov 10, 2010 (Egrifta); deemed a biologics license (BLA 022505) on Mar 23, 2020, so outside the 503A/503B compounding exemptions. Aug 24, 2026: FDA warning letters to five online \"research peptide\" sellers name tesamorelin.", "entry_url": "https://peptlas.com/entries/tesamorelin/", "last_verified": "2026-10-15" }, { "compound": "Tesamorelin", "slug": "tesamorelin", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Not named individually in the Poisons Standard (October 2026), but Appendix D lists growth hormone releasing hormones (GHRHs) as a group among poisons that are illegal to possess without authority. No product on the ARTG.", "entry_url": "https://peptlas.com/entries/tesamorelin/", "last_verified": "2026-10-15" }, { "compound": "Tesamorelin", "slug": "tesamorelin", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation (no tesamorelin product in the MHRA Products database); supply as a medicine would be unlicensed.", "entry_url": "https://peptlas.com/entries/tesamorelin/", "last_verified": "2026-10-15" }, { "compound": "Tesamorelin", "slug": "tesamorelin", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU marketing authorisation: Ferrer Internacional withdrew its application for Egrifta on June 21, 2012, when the CHMP's provisional opinion was that it could not have been approved.", "entry_url": "https://peptlas.com/entries/tesamorelin/", "last_verified": "2026-10-15" }, { "compound": "Tesamorelin", "slug": "tesamorelin", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "On the Prescription Drug List since 2014-04-25 ('Tesamorelin or its salts or derivatives'); both Egrifta DINs are cancelled (2022, 2023), so no product is currently authorized for sale. Named among seized unauthorized peptides (Aug 2025).", "entry_url": "https://peptlas.com/entries/tesamorelin/", "last_verified": "2026-10-15" }, { "compound": "Tesamorelin", "slug": "tesamorelin", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "restricted", "status_label": "Restricted", "note": "Named in S2.2.4 (GHRH and its analogues) on the 2026 and 2027 Prohibited Lists; prohibited at all times.", "entry_url": "https://peptlas.com/entries/tesamorelin/", "last_verified": "2026-10-15" }, { "compound": "Thymosin Alpha-1", "slug": "thymosin-alpha-1", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "in_limbo", "status_label": "In limbo", "note": "Removed from Category 2 (Sept 2024); PCAC declined to recommend it on Dec 4, 2024; not on the 503A list; no approved U.S. product.", "entry_url": "https://peptlas.com/entries/thymosin-alpha-1/", "last_verified": "2026-09-22" }, { "compound": "Thymosin Alpha-1", "slug": "thymosin-alpha-1", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "Regulated as Schedule 4 (prescription-only); the TGA has enforced against unlawful advertising.", "entry_url": "https://peptlas.com/entries/thymosin-alpha-1/", "last_verified": "2026-09-22" }, { "compound": "Thymosin Alpha-1", "slug": "thymosin-alpha-1", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "No UK marketing authorisation; supply for human use treated as an unlicensed medicine.", "entry_url": "https://peptlas.com/entries/thymosin-alpha-1/", "last_verified": "2026-09-22" }, { "compound": "Thymosin Alpha-1", "slug": "thymosin-alpha-1", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "No EU-wide EMA marketing authorisation - thymalfasin holds only an orphan designation (EU/3/02/110) - and is reported as nationally authorised on prescription in Italy as Zadaxin.", "entry_url": "https://peptlas.com/entries/thymosin-alpha-1/", "last_verified": "2026-09-22" }, { "compound": "Thymosin Alpha-1", "slug": "thymosin-alpha-1", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Not authorized for sale; no Drug Product Database listing, and Health Canada named thymosin alpha-1 among unauthorized injectable peptides seized in April 2025.", "entry_url": "https://peptlas.com/entries/thymosin-alpha-1/", "last_verified": "2026-09-22" }, { "compound": "Thymosin Alpha-1", "slug": "thymosin-alpha-1", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not specifically named on the Prohibited List (distinct from thymosin beta-4, which is prohibited).", "entry_url": "https://peptlas.com/entries/thymosin-alpha-1/", "last_verified": "2026-09-22" }, { "compound": "Tirzepatide", "slug": "tirzepatide", "jurisdiction": "United States (FDA)", "regulator": "FDA", "status": "restricted", "status_label": "Restricted", "note": "Enforcement discretion ended Feb 18, 2025 (503A, as announced; the FDA's Sep 2026 Empower letter dates it Mar 5) / Mar 19, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow 503A exception remains. Sep 18, 2026: FDA warning letter to Empower Pharmacy over tirzepatide/niacinamide injections that appear to be essentially copies.", "entry_url": "https://peptlas.com/entries/tirzepatide/", "last_verified": "2026-10-09" }, { "compound": "Tirzepatide", "slug": "tirzepatide", "jurisdiction": "Australia (TGA)", "regulator": "TGA", "status": "restricted", "status_label": "Restricted", "note": "GLP-1 compounding prohibited since Oct 1, 2024; remains Schedule 4.", "entry_url": "https://peptlas.com/entries/tirzepatide/", "last_verified": "2026-10-09" }, { "compound": "Tirzepatide", "slug": "tirzepatide", "jurisdiction": "United Kingdom (MHRA)", "regulator": "MHRA", "status": "restricted", "status_label": "Restricted", "note": "Licensed prescription-only medicine; no legitimate compounding pathway; MHRA enforces against unlicensed product.", "entry_url": "https://peptlas.com/entries/tirzepatide/", "last_verified": "2026-10-09" }, { "compound": "Tirzepatide", "slug": "tirzepatide", "jurisdiction": "European Union (EMA)", "regulator": "EMA", "status": "restricted", "status_label": "Restricted", "note": "Licensed prescription-only medicine EU-wide (Mounjaro, authorised 2022); unauthorised versions cannot be marketed, with pharmacy compounding exemptions and enforcement handled at member-state level.", "entry_url": "https://peptlas.com/entries/tirzepatide/", "last_verified": "2026-10-09" }, { "compound": "Tirzepatide", "slug": "tirzepatide", "jurisdiction": "Canada (Health Canada)", "regulator": "Health Canada", "status": "restricted", "status_label": "Restricted", "note": "Authorized prescription-only medicine (Mounjaro); compounded copies of marketed drugs are not permitted outside a shortage, and Health Canada warns selling unauthorized versions is illegal in Canada.", "entry_url": "https://peptlas.com/entries/tirzepatide/", "last_verified": "2026-10-09" }, { "compound": "Tirzepatide", "slug": "tirzepatide", "jurisdiction": "Sport / anti-doping (WADA)", "regulator": "WADA", "status": "unscheduled", "status_label": "Unscheduled", "note": "Not prohibited; added to the WADA Monitoring Program effective Jan 1, 2026. WADA confirmed GLP-1 status is unchanged for 2027 (Sep 21, 2026).", "entry_url": "https://peptlas.com/entries/tirzepatide/", "last_verified": "2026-10-09" } ] }